KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) EBIT Margin: 2019-2025

Historic EBIT Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -11.41%.

  • Esperion Therapeutics' EBIT Margin rose 1963.00% to -11.41% in Q3 2025 from the same period last year, while for Sep 2025 it was -9.67%, marking a year-over-year decrease of 1524.00%. This contributed to the annual value of 16.37% for FY2024, which is 15009.00% up from last year.
  • Per Esperion Therapeutics' latest filing, its EBIT Margin stood at -11.41% for Q3 2025, which was down 232.45% from 8.61% recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' EBIT Margin peaked at 52.47% during Q1 2024, and registered a low of -1,038.15% during Q1 2021.
  • Its 3-year average for EBIT Margin is -52.20%, with a median of -31.04% in 2024.
  • In the last 5 years, Esperion Therapeutics' EBIT Margin spiked by 300,782bps in 2021 and then slumped by 19,798bps in 2022.
  • Esperion Therapeutics' EBIT Margin (Quarterly) stood at -361.20% in 2021, then soared by 13,528bps to -225.92% in 2022, then skyrocketed by 9,455bps to -131.37% in 2023, then skyrocketed by 12,498bps to -6.40% in 2024, then skyrocketed by 1,963bps to -11.41% in 2025.
  • Its last three reported values are -11.41% in Q3 2025, 8.61% for Q2 2025, and -34.00% during Q1 2025.